Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.88 |
| ▸ | TGM2 | P21980 | 1/20 | 0.68 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.61 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.55 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.55 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL125577 | 1.00 | HTT (0.88) | HTTTGM2FOLH1LMNASMN1; SMN2 | |
| SCHEMBL8674198 | 1.00 | HTT (0.88) | HTTTGM2FOLH1LMNASMN1; SMN2 | |
| SCHEMBL2876850 | 1.00 | HTT (0.88) | HTTTGM2FOLH1LMNASMN1; SMN2 | |
| SCHEMBL3693087 | 1.00 | HTT (0.88) | HTTTGM2FOLH1LMNASMN1; SMN2 | |
| SCHEMBL3694316 | 1.00 | HTT (0.88) | HTTTGM2FOLH1LMNASMN1; SMN2 | |
| SCHEMBL4857273 | 1.00 | HTT (0.88) | HTTTGM2FOLH1LMNASMN1; SMN2 | |
| SCHEMBL4858734 | 1.00 | HTT (0.88) | HTTTGM2FOLH1LMNASMN1; SMN2 | |
| SCHEMBL2875581 | 1.00 | HTT (0.88) | HTTTGM2FOLH1LMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4438046 | 0.98 | HTT (0.86) | HTTTGM2FOLH1LMNASMN1; SMN2 | |
| SCHEMBL879577 | 0.98 | HTT (0.91) | HTTTGM2FOLH1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718157-B1 | Targeted lipid particles | BAKER TERENCE SEWARD | 2010-05-18 | — | — | US | disclosed |
| US-7718157-B1 | Targeted lipid particles | BAKER TERENCE SEWARD | 2010-05-18 | — | — | US | disclosed |
| US-7531676-B2 | Lipids | CELLTECH R & D LIMITED (GB) | 2009-05-12 | — | — | US | disclosed |
| US-7531676-B2 | Lipids | CELLTECH R & D LIMITED (GB) | 2009-05-12 | — | — | US | disclosed |
| US-20060148761-A1 | Lipids | CELLTECH R & D LIMITED | 2006-07-06 | — | — | US | disclosed |
| US-20040024220-A1 | Lipids | CELLTECH R & D LIMITED | 2004-02-05 | — | — | US | disclosed |
| US-6583301-B1 | Bipolar; form complexes with polyanions; delivering bioactive substances such as nucleic acids to cells in vitro and in vivo | CELLTECH R & D LIMITED (GB) | 2003-06-24 | — | — | US | disclosed |
| EP-1204428-A2 | TARGETED LIPID PARTICLES | Celltech R&D Limited (GB) | 2002-05-15 | — | — | EP | disclosed |
| WO-2001012154-A2 | TARGETED LIPID PARTICLES | CELLTECH R&D LIMITED (GB) | 2001-02-22 | — | — | WO | disclosed |
| EP-1070047-A2 | LIPIDS | Celltech Chiroscience Limited (GB) | 2001-01-24 | — | — | EP | disclosed |
| WO-1999052858-A2 | LIPIDS | CELLTECH THERAPEUTICS LIMITED (GB) | 1999-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024220-A1 | Lipids | PHOSPHO1, FABP7, MBOAT7 | HTT 379/4885TGM2 3174/4885FOLH1 714/4885 |
| US-20060148761-A1 | Lipids | PHOSPHO1, FABP7, MBOAT7 | HTT 379/4885TGM2 3174/4885FOLH1 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.